Cochrane · systematic review · CD012814
Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma
Luvira, V, Satitkarnmanee, E, Pugkhem, A, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
9
current version
GRADE rated
5
No studies
4
Included studies
NR
No studies 4 · 44.4%Ungraded 0 · 0%Very low 5 · 55.6%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Adjuvant chemotherapy compared with no chemotherapy for resectable cholangiocarcinoma
Population: people with resectable cholangiocarcinoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality at 5 years Adjuvant chemotherapy vs no chemotherapy | RR 0.92 [0.84, 1.01] | 4 studies · 867 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events Adjuvant chemotherapy vs no chemotherapy | RR 17.82 [2.43, 130.82] | 1 study · 219 participants | Very low Downgraded: risk of bias, imprecision |
Health‐related quality of life Adjuvant chemotherapy vs no chemotherapy | no estimate extracted | NR | No studies |
Cancer‐related mortality Adjuvant chemotherapy vs no chemotherapy | no estimate extracted | NR | No studies |
TIme to recurrence of the tumour Adjuvant chemotherapy vs no chemotherapy | no estimate extracted | NR | No studies |
Non‐serious adverse events Adjuvant chemotherapy vs no chemotherapy | no estimate extracted | NR | No studies |
Adjuvant S‐1 compared to gemcitabine for resectable cholangiocarcinoma
Population: people with resectable cholangiocarcinoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality: 1‐year overall survival Adjuvant S‐1 vs gemcitabine | RR 0.38 [0.15, 0.96] | 1 study · 70 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
All‐cause mortality: 2‐year overall survival Adjuvant S‐1 vs gemcitabine | RR 0.81 [0.58, 1.13] | 1 study · 70 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Serious adverse events Adjuvant S‐1 vs gemcitabine | no estimate extracted | 1 study · 70 participants | Very low Downgraded: risk of bias, imprecision, indirectness |